We report on two patients, successfully treated by the combination therapy of gemcitabine and 24-h intravenous infusion of cisplatin, who were initially diagnosed with node-positive advanced urothelial cancer. Each patient had a very good clinical response and underwent curative radical surgery after gemcitabine/cisplatin chemotherapy. A microscopically detailed examination of surgically obtained specimens showed the complete disappearance of malignant cells in the two cases. As a pilot study, we have used the regimen of gemcitabine plus 24-h continuous infusion of cisplatin, instead of bolus injection, for the treatment of 20 patients with node-positive or metastatic urothelial cancer. The clinical response rate in this regimen was 75% (complete response 7/20; 35%, partial response 8/20; 40%). The median overall survival was 665 days. As for the adverse effects, the incidences of severe neutropenia and thrombocytopenia (grade 3-4) were 20% and 15%, which might be less toxic than conventional gemcitabine plus cisplatin therapy. The 24-h infusion of cisplatin combined with gemcitabine can be highly recommended as neoadjuvant chemotherapy for locally advanced urothelial cancer.
INTRODUCTION
Chemotherapy is the main treatment for nodepositive or metastatic urothelial carcinoma [1, 2] . The sensitivity of urothelial cancer to chemotherapy was noted in the 1970s and platinum based regimens such as MVAC (methotrexate, vinblastin, doxorubicin, and cisplatin) resulted in responses consisitently exceeding 50% [3, 4] . Newer agents including taxanes and gemcitabine were found to be active in the 1990s [5, 6] . The reports comparing MVAC with gemcitabine/ cisplatin demonstrated the equivalence of the two regimens [7, 8] . Because it shows the comparable antitumor effects with less toxicity, compared to MVAC regimen, the combination therapy of gemcitabine plus cisplatin is now commonly used as a first line therapy for metastatic urothelial cancer [9] . However, in the neoadjuvant settings, a comprehensive evaluation of this combination therapy is still lacking [10] .
Although considerable progress has been made in supportive care and emesis control [11, 12] , renal functions of the patients with advanced urothelial cancer are sometimes impaired [13] partly because of the urinary obstruction by tumor invasion. We have used 24-h continuous infusion of cisplatin [14, 15] , *Address correspondence to this author at the Department of Medical Oncology, Nagoya Memorial Hospital, 4-305 Hirabari, Tenpaku-ku, Nagoya 468-8520, Japan; Tel: +81-52-804-1111; Fax: +81-52-803-8830; E-mail: kina@hospy.or.jp instead of bolus injection, in combination with gemcitabine for the treatment of node-positive or metastatic urothelial cancer patients, including cisplatin-unfit patients, since 2005.
PATIENTS AND METHODS
Patients were eligible if they signed the informed consent form and met all the following criteria: pathologically proven transitional cell carcinoma (TCC) or clinically diagnosed as node-positive or metastatic urothelial cancer; age 20-85 years; Eastern Cooperative Oncology Group performance status of 0-3; no prior chemotherapy; a white blood cell count between 4,000 and 12,000/mm Response Evaluation Criteria in Solid Tumors (RECIST) and National Cancer Institute common toxicity criteria (NCI-CTC) version 4.0 were applied to evaluate antitumor effects and adverse effects, respectively. Overall survival (OS) was calculated from the start of chemotherapy to death or the latest follow-up day. The Kaplan-Meier method was used to plot OS curves.
RESULTS
In this pilot study, we enrolled 20 patients with node-positive or metastatic urothelial cancer from July, 2005 to June, 2013 ( Table 1) . The overall response rate was 75% (15/20) ( Table 2) . Among them, the pathologically complete response was demonstrated in two cases, which was confirmed by a histologically detailed evaluation of the resected specimens of the primary tumor and surrounding lymph nodes. Grade 3-4 toxicities were neutropenia (20%) and thrombocytopenia (15%) ( Table 3a) . As for nonhematological toxicities, three cases (Case 6, 9, 20) stopped due to progress in renal dysfunction and one (Case 14) ceased because of interstitial pneumonia ( Table 1, 
Case 1
A 59-year old man admitted because of gross hematuria and acute renal failure (BUN 29 mg/dL, Creatinine 2.24 mg/dL, eGFR 25 ml/min). Computed tomography (CT) scan image showed 60 x 40 mm size mass in the bladder, which caused bilateral urinary tract obstruction, and swollen para-aortic lymph nodes without any distant metastases (T3N2M0) (Figure 2A ). After renal drainage was constructed, renal function was improved (BUN 20 mg/dL, Creatinine 1.39 mg/dL, eGFR 35 ml/min, Creatinine clearance 32 ml/min). And then chemotherapy was initiated on February 28, 2012 and 24-h infusion of cisplatin was performed at a dose of 20 mg/m 2 . Grade 3 neutropenia was observed during the chemotherapy and despite of recurrent urinary tract infection renal function was gradually improved to 52 ml/min of creatinine clearance. Consequently, the chemotherapeutic efficacy was diagnosed as partial response (PR) after 3 courses. A reevaluation after 9 courses of this therapy showed only a small elevated lesion in the bladder with no swollen lymph nodes ( Figure 2B ). Although the patient was well informed that cystectomy was not curative, he underwent surgery in the hope of cure. We performed radical cystectomy with pelvic lymph node dissection on September 26, 2012. A microscopic examination of the resected specimens revealed the complete disappearance of cancer cells at the site of the primary lesion ( Figure 3A, B) . 
Case 6
A 72-year old man consulted our hospital because of gross hematuria. Magnetic resonance image (MRI) showed the left ureteral tumor (20 x 30 mm) with bladder invasion and lymph node enlargement in the internal iliac region (Figure 4A) . Endoscopic biospsy samples showed TCC with grade 2 ( Figure 5A) . As a provisional diagnosis of T4N1M0, combination therapy of gemcitabine and cisplatin was started on August 30, 2012. The dose of cisplatin was reduced to 30 mg/m 2 , because eGFR was less than 60 ml/min. Cisplatin was dissolved into 1000 ml of saline and then continuously infused for 24-h. After two courses of this chemotherapy, eGFR was further decreased to 32 ml/min and, therefore, cisplatin was replaced by oxaliplatin. Another 4 courses of chemotherapy were administered and then MRI showed complete response (CR) ( Figure 4B ) and cystoscopic examination showed a disappearance of malignant tumors. Radical Surgery was performed on February 6, 2013. A microscopic examination using multiple sections of the resected primary lesions and lymph nodes showed a pathological CR (Figure 5B ).
CONCLUSIONS
The clinical response rate in our regimen using a 24-h continuous infusion of cisplatin combined with gemcitabine was 75% (CR 7/20; 35%, PR 8/20; 40%). In this pilot study, the median OS of our 20 cases was 665 days [16] [17] [18] [19] . Table 4 presents the results of our study in comparison with currently accepted first-line regimens containing gemcitabine for the treatment of advanced urothelial cancer. The recent randomized phase III trial showed that triple combination of cisplatin, gemcitabine, and paclitaxel provided a higher response rate than the combination of gemcitabine plus cisplatin (55.5% versus 43.6%), however, survival benefit did not reach statistical difference (median OS 15.8 months versus 12.7 months) [16] . Considering the results of this randomized study, chemotherapeutic activities of our regimen should be comparable, although the number of cases in our pilot study was very small.
With regard to adverse effects, the incidences of severe (grade 3-4) neutropenia and thrombocytopenia were 20.0% and 15.0%, respectively, which 
B:
A detailed histological examination of surgically resected specimens showed that no malignant cells were observed at the site of the primary lesion (B-1) and regional lymph nodes (B-2). might be less toxic than conventional combination therapy of gemcitabine plus cisplatin [7, 16, 20] . On the contrary, renal toxicities were observed in 15.0% (3/20), whose incidence was rather high [7, 16, 21] . It is mainly because our study included the patients with poor renal functions (eGFR < 40 ml/min 2 cases; 40-60 ml/min 6 cases) as well as cisplatin-fit patients (eGFR > 60 ml/min 12 cases). We reduced the dose of cisplatin according to their renal functions, however, we repeated chemotherapy as much as possible (cycle numbers 2-11). Accordingly, twelve patients received more than 5 cycles of chemotherapy and the response rate was comparable to the previous reports [7, 16] . As a result three out of 15 responders to this combination therapy were successfully treated with surgery and two of them revealed a pathological CR. A histologically detailed examination of their resected specimens showed complete disappearance of cancer cells, therefore, no postoperative adjuvant therapy was performed [22, 23] . These two cases are free of recurrence at 23 and 7 months after the surgical resection and at 31 and 24 months after the initiation of the combination therapy, respectively.
In conclusion, the combined therapy of 24-h infusion of cisplatin with gemcitabine is considered to be active and well-tolerated regimen even for the cisplatin-unfit patients with urothelial carcinoma, although the dose reduction of cisplatin may be needed.
SUPPORTING FOUNDATIONS
No funding was received.
